Farmalipon (a-lipoic acid) solution for infusions 30 mg/ml. 20 ml. №5 vial


Manufacturer: Ukraine

Paresthesia in diabetic polyneuropathy.



Farmalipon Storage
active substance: thioctic (a-lipoic) acid;

1 ml of solution contains thioctic (a-lipoic) acid 30 mg;

Excipients: meglumine, macrogol 300, water for injections.

Farmalipon Dosage form
Solution for infusion.

Main physical and chemical properties: clear yellow or greenish-yellow solution.

Pharmacotherapeutic group
Drugs that affect the digestive system and metabolic processes. Code ATX A16A X01.

Pharmacological properties


Thioctic (a-lipoic) acid is a substance that is synthesized in the body and acts as a coenzyme in the oxidative decarboxylation of α-keto acids; plays an important role in the process of energy production in the cell. Helps reduce blood sugar and increase the amount of glycogen in the liver. Lack or disruption of thioctic (a-lipoic) acid metabolism due to intoxication or excessive accumulation of some breakdown products (eg, ketone bodies) leads to disruption of aerobic glycolysis. Thioctic (a-lipoic) acid can exist in two physiologically active forms (oxidized and reduced), which have antitoxic and antioxidant effects.

Thioctic (a-lipoic) acid affects cholesterol metabolism, participates in the regulation of lipid and carbohydrate metabolism, improves liver function (due to hepatoprotective, antioxidant, detoxifying effects). Thioctic (a-lipoic) acid is similar in pharmacological properties to B vitamins.


Thioctic (a-lipoic) acid undergoes significant changes during the primary passage through the liver. Significant interindividual fluctuations in the systemic availability of thioctic (a-lipoic) acid are observed. Excreted by the kidneys mainly as metabolites. The formation of metabolites occurs as a result of side chain oxidation and conjugation. The half-life of thioctic (a-lipoic) acid from serum is 10-20 minutes.

Paresthesias in diabetic polyneuropathy.

Farmalipon Contraindication
Hypersensitivity to thioctic (α-lipoic) acid or to other components of the drug.
Heart and respiratory failure.
Acute phase of myocardial infarction.
Acute cerebrovascular accident.
Chronic alcoholism and other conditions that can lead to lactic acidosis.
Interaction with other medicinal products and other forms of interaction
Thioctic (a-lipoic) acid reacts with metal ion complexes (eg, cisplatin), so the drug may reduce the effect of cisplatin.

With sugar molecules, thioctic (a-lipoic) acid forms sparingly soluble complex compounds.

Thioctic (a-lipoic) acid is a metal chelator, so it cannot be used with metals (eg iron, magnesium).

Ethanol reduces the therapeutic efficacy of thioctic (a-lipoic) acid.